Last reviewed · How we verify
Tetraspan
Tetraspan is a Small molecule drug developed by Haukeland University Hospital. It is currently in Phase 2 development. Also known as: Tetraspan® (HES 130/0,42 , 6%),, B. Braun Medical AS, Kjernåsveien 13 B, 3142 Vestskogen.
Tetraspan is being studied in clinical trials for conditions such as ischemic heart disease, coronary artery disease, and head trauma, among others. It is being tested in combination with interventions like acute normovolemic hemodilution and a Balanced hydroxyethyl starch solution.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Tetraspan |
|---|---|
| Also known as | Tetraspan® (HES 130/0,42 , 6%),, B. Braun Medical AS, Kjernåsveien 13 B, 3142 Vestskogen |
| Sponsor | Haukeland University Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Impact of Acute Normovolemic Hemodilution on Blood Viscosity (NA)
- Comparing Human Albumin Versus Hydroxyethylstarch in Renal Transplant Recipients (NA)
- Effects of Different Strategy of Fluids Administration on Acid/Base Disorders and Inflammatory Mediators (NA)
- Effect of Prime Solution on Fluid Balance After Open Heart Surgery (PHASE4)
- Fluid Investigation Colloid vs Crystalloid Reg. Renal Hemodynamics and Function (NA)
- The Effect on Fluid Balance After Cardiac Surgery After Use of Two Different Priming Protocols (PHASE2)
- The Effect of Intravenous Prehydration on the Hemodynamic Status of Healthy Parturients Undergoing Spinal Anesthesia for Cesarean Delivery (NA)
- Interest of Using Balanced Fluid for Infusion at the Early Phase of an Acute Cranial Trauma for Limiting Hyperchloremic Acidosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tetraspan CI brief — competitive landscape report
- Tetraspan updates RSS · CI watch RSS
- Haukeland University Hospital portfolio CI
Frequently asked questions about Tetraspan
What is Tetraspan?
Who makes Tetraspan?
Is Tetraspan also known as anything else?
What development phase is Tetraspan in?
Related
- Manufacturer: Haukeland University Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Tetraspan® (HES 130/0,42 , 6%),, B. Braun Medical AS, Kjernåsveien 13 B, 3142 Vestskogen
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing